🌍·13h agodiscovery
Syntara's FDA-Backed Amsulostat Advances to Phase 2b Myelofibrosis Trial as Clinical Pipeline Delivers Multiple Data Catalysts
Publisher
K
Kalkine
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Kalkine
- Region
- Global
- Scope
- discovery
- Published
- July 27, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: Kalkine
Scope: discovery
Related coverage
More related coverage
Stock Titan/2h ago
OKYO Pharma (Nasdaq: OKYO) plans Phase 3 NCP trial, joins BTIG conference
Stock Titan/2h ago
VERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigens
Stock Titan/2h ago
OKYO Pharma plans 111-patient Phase 3 corneal pain trial
marketscreener.com/2h ago